Target intelligence / Profile preview

Dynamin-like GTPase OPA1, mitochondrial (OPA1) (OPA1)

Target
OPA1
Molecular classification
Enzyme, Other
01

Overview

Dynamin-like GTPase OPA1, mitochondrial is a critical protein located within the inner mitochondrial membrane (IMM) that governs mitochondrial dynamics and organelle architecture [1, 5, 8]. Its primary function involves mediating the fusion of the IMM and maintaining the integrity of mitochondrial cristae, which are essential for efficient oxidative phosphorylation and ATP synthesis [2, 6, 12]. Furthermore, OPA1 plays a pivotal role in regulating apoptosis by sequestering cytochrome c within the cristae, thereby acting as a molecular gatekeeper against premature cell death [6, 11, 15]. Mutations in the OPA1 gene are the primary cause of autosomal dominant optic atrophy (DOA), a condition leading to progressive retinal ganglion cell loss and blindness, and are also associated with multi-systemic 'OPA1-plus' syndromes [2, 17, 20]. In oncology, OPA1 has emerged as a therapeutic target because its inhibition can disrupt the mitochondrial network and cristae structure in malignant cells, triggering apoptosis and overcoming resistance to chemotherapy [1, 12, 14]. Experimental small-molecule inhibitors such as BTM-3566 are currently being investigated for their potential to treat hematologic and solid tumors by modulating these mitochondrial dynamics [12, 14, 22].

Other names
Optic atrophy protein 1Dynamin-like 120 kDa protein, mitochondrialMGM1NPGNTGOptic atrophy 1largeGBERHSMTDPS14
02

Mechanism of action

Inhibition of OPA1 leads to mitochondrial fragmentation, disruption of cristae architecture, and the release of pro-apoptotic factors like cytochrome c to induce cell death in cancer; activation or stabilization of OPA1 promotes mitochondrial fusion and preserves bioenergetics in neurodegenerative contexts.

03

Biological functions

Mitochondrial fusionCristae organizationApoptosisOxidative phosphorylationMitochondrial DNA maintenance
04

Disease associations

Optic atrophyCancerNeurodegenerative diseaseCardiovascular diseaseChronic obstructive pulmonary disease
05

Safety considerations

Haploinsufficiency-induced vision lossRisk of systemic mitochondrial dysfunctionPotential cardiotoxicityPotential neurotoxicityEmbryonic lethality
06

Interacting drugs

BTM-3566

9 more in the full profile.

07

Biomarkers

Peripapillary retinal nerve fiber layer thicknessOPA1 protein expression levelsMitochondrial DNA copy numberMitochondrial morphology

Beyond the preview

Go deeper on Dynamin-like GTPase OPA1, mitochondrial (OPA1) (OPA1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Dynamin-like GTPase OPA1, mitochondrial (OPA1) (OPA1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call